Equities

3-D Matrix Ltd

7777:TYO

3-D Matrix Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)126.00
  • Today's Change2.00 / 1.61%
  • Shares traded143.10k
  • 1 Year change-37.93%
  • Beta1.2971
Data delayed at least 20 minutes, as of Mar 29 2024 01:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

  • Revenue in JPY (TTM)3.74bn
  • Net income in JPY-1.06bn
  • Incorporated2004
  • Employees108.00
  • Location
    3-D Matrix Ltd7FKojimachi HF Bldg., 3-2-4, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 335113440
  • Fax+81 335113402
  • Websitehttps://www.3d-matrix.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chiome Bioscience Inc682.46m-1.22bn7.86bn51.00--6.50--11.52-24.67-24.6713.7722.000.34414.196.8813,381,650.00-61.51-50.50-79.81-57.3858.4157.53-178.77-224.742.90-513.930.2009--8.1926.241.84------
Wakamoto Pharmaceutical Co Ltd7.98bn-177.67m7.91bn292.00--0.673334.000.9912-5.12-5.12229.89337.150.5252.082.8827,324,600.00-1.17-2.58-1.34-3.0046.9853.08-2.23-4.333.45--0.0085--3.31-4.50-42.041.88-17.490.00
Noile-Immune Biotech Inc316.82m-1.13bn7.92bn19.00--1.39--25.00-27.44-27.447.64131.420.06080.1818-----21.69---22.60--99.29---356.68--66.04-------49.37---192.28------
Carna Biosciences, Inc.1.63bn-1.15bn8.03bn65.00--2.07--4.94-69.84-69.8496.78226.160.37741.363.35---26.76-14.45-29.55-16.9589.2290.59-70.91-35.4210.78-312.970.0451--17.2416.5914.57---27.69--
Symbio Pharmaceuticals Ltd5.59bn-1.96bn8.34bn109.00--1.09--1.49-48.74-48.74139.70170.890.60093.363.7351,281,720.00-21.10-19.18-24.97-23.6278.9165.84-35.11-24.328.21--0.00---44.157.82-266.45--42.39--
CanBas Co Ltd (Parent)0.00-1.07bn8.47bn12.00--2.69-----64.96-64.960.00174.810.00----0.00-40.62-65.86-42.95-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc246.60m-1.07bn9.00bn10.00--8.55--36.51-42.31-42.319.9441.170.10232.2029.1624,660,200.00-44.25---64.34---182.07---432.63--1.92-417.040.1046--48.96---41.18------
Stella Pharma Corp254.09m-765.17m9.18bn46.00--3.44--36.13-25.23-25.238.3285.550.06370.04563.585,523,718.00-19.18---20.37--82.76---301.14--11.90-1,173.120.2671--128.85---1.45------
DNA Chip Research Inc431.66m-284.71m9.83bn36.00--20.78--22.77-45.19-45.1968.7774.440.67288.525.3111,990,420.00-44.38-21.72-55.27-24.436.0217.16-65.96-50.031.90--0.00---23.46-2.03-170.31--33.58--
Linical Co Ltd12.52bn680.40m9.99bn759.0013.411.178.400.798430.1230.12554.28346.380.7251--3.9916,494,230.003.944.716.557.2333.1031.605.435.98--17,809.030.279345.368.326.5527.06-4.97-33.014.94
3-D Matrix Ltd3.74bn-1.06bn10.00bn108.00--16.27--2.67-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
TMS Co Ltd0.00-672.08m11.45bn14.00--3.29-----19.49-19.490.0086.330.00----0.00-18.60---19.25-------------1,585.970.00---100.00---179.95------
KOEI CHEMICAL COMPANY, LIMITED18.49bn62.58m11.53bn387.00183.910.53023.920.623712.7912.793,779.784,437.990.45991.304.5147,770,930.000.15573.760.2064.6824.9124.120.33856.660.53561.770.308935.807.550.4997-26.56-33.8215.6820.11
Veritas In Silico Inc-100.00bn-100.00bn12.39bn15.00--7.63----------250.48------------------------16.13--0.00--201.37--39.14------
Healios KK121.00m-3.82bn12.62bn71.00--2.71--104.28-55.07-55.071.7851.710.008--0.3929---25.27-23.55-35.99-28.5283.47---3,152.89-6,580.16---13.680.6756--34.44--26.04---22.00--
Data as of Mar 29 2024. Currency figures normalised to 3-D Matrix Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.22%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 19 Dec 2023172.50k0.22%
Heights Capital Management, Inc.as of 12 Jan 202434.000.00%
Data from 31 Dec 2023 - 14 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.